Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$210.60M$210.60Mderived+7.1% vs Q4 2023 Net Income-$42.50M-$42.50MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$150,900,000— Operating Incomederived-$39,100,000N/M Operating Cash Flowderived$6,600,000N/M Margins · derivedGross margin71.7%
Operating margin-18.6%−2.6 pt vs Q4 2023
Net margin-20.2%−4.3 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 28, 2025 · 59 d after period end